Enterprise Value

104.7M

Cash

477M

Avg Qtr Burn

-27.26M

Short % of Float

14.67%

Insider Ownership

1.76%

Institutional Own.

-

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tipifarnib Details
Head and neck cancer, Cancer, Head and neck squamous cell carcinoma

Phase 2

Data readout

Tipifarnib Details
Cancer, T-cell lymphoma, Lymphoma

Phase 2

Update

Phase 2

Update

Tipifarnib + alpelisib Details
Head and neck cancer, Head and neck squamous cell carcinoma, Cancer

Phase 1/2

Update

KO-2806 (FTI inhibitor) Details
Solid tumor/s, Non-small cell lung carcinoma

Phase 1

Data readout

Phase 1

Data readout

KO-2806 (FTI inhibitor) + cabozantinib Details
Solid tumor/s, Renal cell carcinoma

Phase 1

Initiation

Phase 1

Initiation